Skip to content
Screener

Vor Biopharma VOR Operating Lease Liabilities (Total)

Operating Lease Liabilities (Total) at other companies

Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
$1.36M-2.3%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$2.07M+36.3%
Kyverna Therapeutics, Inc. logo
Kyverna Therapeutics, Inc.KYTX
$8.72M
Janux Therapeutics logo
Janux TherapeuticsJANX
$20.99M-5.4%

Other financials

Income statement

See full
Operating income-$35.2M-5.6%
Net income-$219.6M-576%
EPS (diluted)-$5.11+1.9%

Balance sheet

See full
Cash & equivalents$169.9M+239%
Total debt$2.9M-90.5%
Total equity-$150.4M-328%
Total assets$506.7M+364%

Cash flow

See full
Operating cash flow-$38.2M-23.1%
CapEx$48.0K-79.2%
Free cash flow-$38.3M-22.4%

Valuation

See full
Market cap$1.28B+416%
Enterprise value$1.12B+902%

Returns & leverage

See full
Return on equity-125.4%+671pp
Debt / equity0.5×+0.2×
Current ratio31.1×+27.3×

Where this comes from

Reported directly by Vor Biopharma in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiability.

The source filing: Vor Biopharma’s 10-Q, filed May 13, 2026.

Filed
May 13, 2026, 8:31 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-220689
(in thousands except weighted-average amounts)March 31, 2026December 31, 2025
Operating lease right-of-use assets$2,827$2,936
Liabilities
Operating lease liabilities, current$307$280
Operating lease liabilities, non-current2,6322,720
Total lease liabilities$2,939$3,000
Weighted-Average Lease Term and Discount Rate
Weighted-average remaining lease term (years)5.45.7
Weighted-average discount rate6.7%6.7%

Item 1. Financial Statements (Unaudited).

FAQ

What is Vor Biopharma's operating lease liabilities (total)?
Vor Biopharma (VOR) reported operating lease liabilities (total) of $2.94M in Q1 2026.
How has Vor Biopharma's operating lease liabilities (total) changed year-over-year?
Vor Biopharma's operating lease liabilities (total) decreased by 90.5% year-over-year, from $30.78M to $2.94M.
What is the long-term trend for Vor Biopharma's operating lease liabilities (total)?
Over 5 years (2020 to 2025), Vor Biopharma's operating lease liabilities (total) has grown at a -30.3% compound annual growth rate (CAGR), from $18.29M to $3M.
What does operating lease liabilities (total) mean?
This represents the total present value of future lease payments for operating leases, recognized as a liability on the balance sheet. It reflects the company's long-term commitment to leased assets such as office space, warehouses, and equipment. Tracking this helps investors evaluate the company's off-balance-sheet financing obligations and overall debt-like commitments.

Ask your AI about Vor Biopharma's operating lease liabilities (total).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude